Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Mantle-Cell 13Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 5Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Glioblastoma 1Cardiovascular Diseases 1Anemia, Hemolytic, Autoimmune 1

Interventions

Rituximab 13Cyclophosphamide 10Lenalidomide 8venetoclax 5ibrutinib 5fludarabine 4CT-P10 4orelabrutinib 3obinutuzumab 3fludarabine phosphate 3Vincristine 3tafasitamab 2pirtobrutinib 2copanlisib 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Melphalan 2Magnetic Resonance Spectroscopy 2Hyaluronoglucosaminidase 2Etoposide 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2selinexor 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell, Marginal Zone × acalabrutinib × Clear all
NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Active not recruiting
26 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Acerta Pharma BV

Phase 1/2 Active not recruiting
113 enrolled 19 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡